https://doi.org/10.4081/aiua.2022.3.369
How long should we follow patients managed for muscle-invasive bladder cancer? Lesson learned from a recent clinical practice
Submitted: June 14, 2022
Accepted: June 17, 2022
Published: September 26, 2022
Accepted: June 17, 2022
Abstract Views: 528
PDF: 265
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
To the Editor,
The exact time to stop bladder cancer patient’s follow-up is not well known and there is not a clear recommendation on if and when stop to follow a patient managed for muscle invasive bladder cancer (MIBC). Major urological guidelines do not provide a precise indication on the timing of follow-up, and there is currently no real consensus on optimal time schedule [...].
Muscle-invasive and Metastatic Bladder Cancer - FOLLOW-UP - Uroweb. Accessed May 29, 2022. https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer/chapter/followup
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline (Amended 2020) - American Urological Association. Accessed May 29, 2022. https://www.auanet.org/guidelines/guidelines/bladder-cancer-non-metastatic-muscle-invasive-guideline
Matsumoto K, Kikuchi E, Horiguchi Y, et al. Late recurrence and progression in non-muscle-invasive bladder cancers after 5-year tumor-free periods. Urology. 2010; 75:1385-1390.
DOI: https://doi.org/10.1016/j.urology.2009.09.088
Yoo SH, Kim H, Kwak C, Kim HH, Jung JH, Ku JH. Late recurrence of bladder cancer following radical cystectomy: characteristics and outcomes. Urol Int. 2019; 103:291-296.
DOI: https://doi.org/10.1159/000502656
Hautmann RE, Volkmer B, Egghart G, et al. Functional outcome and complications following Ileal neobladder reconstruction in male patients without tumor recurrence. More than 35 years of experience from a single center. J Urol. 2021; 205:174-182.
DOI: https://doi.org/10.1097/JU.0000000000001345
Stewart-Merrill SB, Boorjian SA, Thompson RH, et al. Evaluation of current surveillance guidelines following radical cystectomy and proposal of a novel risk-based approach. Urol Oncol Semin Orig Investig. 2015; 33:339.e1-339.e8.
DOI: https://doi.org/10.1016/j.urolonc.2015.04.017
Mantica G, Simonato A, Du Plessis DE, et al. The pathologist’s role in the detection of rare variants of bladder cancer and analysis of the impact on incidence and type detection. Minerva Urol e Nefrol. 2018; 70:594-597.
DOI: https://doi.org/10.23736/S0393-2249.18.03175-2
Sawazaki H, Arai Y, Ito Y, et al. Expression of L-type amino acid transporter 1 is a predictive biomarker of intravesical recurrence in patients with non-muscle invasive bladder cancer. Res Reports Urol. 2021; 13:603.
DOI: https://doi.org/10.2147/RRU.S326249
Saoud R, Sanford TH, Hewitt SM, Apolo AB, Agarwal PK. Rapidly progressing urothelial carcinoma due to a rare TP53 (p.Arg110Pro) mutation: a case report and review of the literature. Res reports Urol. 2021; 13:181-184.
DOI: https://doi.org/10.2147/RRU.S288948
Singh R, Singh UP, Agrawal V, Garg M. Epithelial-to-mesenchymal transition based diagnostic and prognostic signature markers in non-muscle invasive and muscle invasive bladder cancer patients. Mol Biol Rep. 2022; 49:7541-7556.
DOI: https://doi.org/10.1007/s11033-022-07563-2
van Osch FHM, Jochems SHJ, Reulen RC, et al. The association between smoking cessation before and after diagnosis and non-muscle-invasive bladder cancer recurrence: a prospective cohort study. Cancer Causes Control. 2018; 29:675.
DOI: https://doi.org/10.1007/s10552-018-1046-8
Jensen BT, Lauridsen SV, Jensen JB. Optimal delivery of follow-up care after radical cystectomy for bladder cancer. Res Reports Urol. 2020;12:471.
DOI: https://doi.org/10.2147/RRU.S270240
Borghi C, Manservigi M, Milandri ES, Greco P, Ippolito C, Dell’Atti. The impact of orthotopic reconstruction on female sexuality and quality of life after radical cystectomy for non-malignant bladder conditions. Arch Ital di Urol e Androl. 2021; 93:255-261.
DOI: https://doi.org/10.4081/aiua.2021.3.255
How to Cite
De Rose, A. F., Vecco, F., Ambrosini, F., Malinaric, R., Mantica, G., & Terrone, C. (2022). How long should we follow patients managed for muscle-invasive bladder cancer? Lesson learned from a recent clinical practice. Archivio Italiano Di Urologia E Andrologia, 94(3), 369–370. https://doi.org/10.4081/aiua.2022.3.369
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.